Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
|Articles|January 22, 2010
Pharma Unplugged Episode #4 - Give Until It Hurts
GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged.
Advertisement
Give Until It Hurts
Pharma Unplugged Podcast Series
Recorded: 1/15/2010
Air Date: 1/22/2010
Host: George Koroneos, Pharm Exec
Cohosts: Reid Paul, Pharm Rep Magazine & Oriana Schwindt
Download Adobe Flash Player
GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged—Give Until It Hurts
This week we discuss:
- Pharma donations to Haiti
- GAO pricing report
- FDA transparency initiative
- Most viewed branded Web sites via TV ads
- Merck submits Gardasil data
Episode# 3
Top Five Trends and News Stories in 2009
Episode# 2
Layoffs and Bonuses
Episode# 1
A Link Apart : FDA Social Media Hearing
Advertisement
Related to this article
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
Viatris Acquires Pacira BioSciences for $1.65 Billion
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
5